secwatch / observer
8-K filed December 21, 2022, 6:59 PM ET ticker SCNX CIK 0001382574
other material confidence high sentiment neutral materiality 0.15

TRxADE HEALTH stockholders approve issuance of up to 2,663,045 shares upon exercise of warrants

Scienture Holdings, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Scienture Holdings, Inc. shareholders approved Approval of issuance of up to 2,663,045 shares of common stock upon exercise of Private Placement Warrants at the 2022-12-20 meeting.

Outcome
passed
Meeting
2022-12-20
Exact text from the filing
1. Proposal No. 1: To approve the issuance of up to 2,663,045 shares of our common stock upon exercise of an outstanding common stock purchase warrant (the “ Private Placement Warrants ”), in accordance with the Nasdaq Listing Rules (the “ Warrant Share Issuance Proposal ”): For Against Abstentions Broker Non-Votes 5,557,740 11,610 2,640 0 Proposal No. 1 was approved by approximately 99.7% of the aggregate total of shares of common stock voted at the Special Meeting, and as such Proposal No. 1 was approved by the stockholders.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Scienture Holdings, Inc. shareholders approved Adjournment of Special Meeting if necessary to solicit additional proxies at the 2022-12-20 meeting.

Outcome
passed
Meeting
2022-12-20
Exact text from the filing
2. Proposal No. 2: To approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposal to approve the Warrant Share Issuance Proposal: For Against Abstentions Broker Non-Votes 5,519,397 48,893 2,700 0
View on SEC.gov

562 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Scienture Holdings, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-22-036149
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.